

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Contents lists available at ScienceDirect



Travel Medicine and Infectious Disease

journal homepage: www.elsevier.com/locate/tmaid

Correspondence

A family cluster of COVID-19 involving an asymptomatic case with persistently positive SARS-CoV-2 in anal swabs

To the Editor,

In December 2019, coronavirus disease 2019 (COVID-19) emerged in Wuhan, China and spread throughout the world rapidly [1,2]. Several studies have described the epidemiologic and clinical characteristics of COVID-19 patients [1–3]. The clinical spectrum of COVID-19 varies from mild to critically illness [3]. We report a family cluster of two patients with COVID-19 involving an asymptomatic case with normal blood routine tests and chest CT images but positive of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid in swab samples, especially in anal swab samples.

A 35-year-old woman (Patient 1) with a 1-day history of fever and





Fig. 1. Course of illness of a family cluster of patients with SARS-CoV-2 infection.

https://doi.org/10.1016/j.tmaid.2020.101745 Received 18 March 2020; Received in revised form 12 May 2020; Accepted 13 May 2020 Available online 16 May 2020 1477-8939/ © 2020 Elsevier Ltd. All rights reserved. cough was admitted to a local hospital in Suqian, China, on Feb 13, 2020 (Fig. 1). A throat swab sample was collected for the screening of SARS-CoV-2 nucleic acid and tested positive for SARS-CoV-2 nucleic acid by real-time polymerase chain reaction according to the recommended protocol [4]. This patient was isolated and transferred to the designated hospital in Suqian, China for further treatment. She had a suspect contact history of confirmed COVID-19 cases within two weeks of symptom onset. She presented normal lymphocytes but significantly elevated C-reactive protein level on admission. The chest CT images presented ground-glass opacities in both lungs. After treatment, her fever disappeared on Feb 16. Her throat swab samples were confirmed to be negative for SARS-CoV-2 nucleic acid on Feb 29. As shown in Fig. 1, the Patient 1 had been tested negative for SARS-CoV-2 nucleic acid in anal swab samples during hospitalization. All the symptoms disappeared and she was discharged on Mar 02.

A 54-year-old woman (Patient 2), the mother-in-law of Patient 1, who lived together with Patient 1 was asked for the screening of SARS-CoV-2 nucleic acid and tested positive for SARS-CoV-2 nucleic acid in throat swab sample on Feb 15. She was immediately transferred to the designated hospital for isolation and treatment in Suqian, China. She had no signs or clinical symptoms, with normal blood routine tests. Her chest CT images did not show significant abnormalities. After admission, she was treated with lopinavir-ritonavir, arbidol, and atomized inhalation of interferon α -2b. During the hospitalization, she was completely asymptomatic. The throat swab sample became negative for SARS-CoV-2 nucleic acid on Feb 18. However, as shown in Fig. 1, the Patient 2 was positive for SARS-CoV-2 nucleic acid in anal swab samples on Feb 18, 20, 24, and 26. The SARS-CoV-2 nucleic acid became negative in anal swab sample on Feb 28. Both anal and throat swab samples were tested negative for SARS-CoV-2 nucleic acid on Feb 29. She was discharged on Mar 03.

This family cluster of COVID-19 patients involved an asymptomatic case (Patient 2) who was diagnosed with COVID-19 by SARS-CoV-2 nucleic acid screening. After treatment, the SARS-CoV-2 nucleic acid became negative in throat swab samples, while the anal swab samples continued to be positive for SARS-CoV-2 nucleic acid for at least 9 days. However, several reports noted that the anal swab samples from some COVID-19 patients were positive for SARS-CoV-2 nucleic acid [5-8]. Fan et al. reported an infant with COVID-19 who was negative for SARS-CoV-2 nucleic acid in oropharyngeal specimen on the 14th day after onset of the illness while the anal swab was still positive for SARS-CoV-2 nucleic acid on the 28th day after the illness onset [5]. Liu et al. reported an 8-year-old boy who was positive for SARS-CoV-2 nucleic acid in anal swab for at least 9 days after discharge [6]. Wu et al. analyzed the SARS-CoV-2 nucleic acid in various biological samples of COVID-19 patients and found that the positive rate of SARS-CoV-2 nucleic acid in anal swabs was 10.00% [7]. Zhang et al. also found the presence of SARS-CoV-2 nucleic acid in anal swabs and more anal swab positives than oral swab positives in a later stage of infection [8]. However, few studies reported the presence of SARS-CoV-2 nucleic acid in anal swabs in asymptomatic adult patients. Our study reported an asymptomatic adult patient who was positive for SARS-CoV-2 nucleic acid in anal swab samples for at least 9 days after the SARS-CoV-2 nucleic acid became negative in throat swab samples. Thus, the possibility of fecal-oral transmission by asymptomatic carriers need to be taken into account. This family cluster of COVID-19 provides important evidence that individuals with family members infected by SARS-CoV-2 should be closely monitored and tested for SARS-CoV-2 nucleic acid both in anal and throat swab samples to rule out infection, even if they do not present any symptom.

Funding

This study was supported by the Fundamental Research Funds for the Central Universities (No. 14380459).

Declaration of competing interest

None of the authors has any conflict of interest to declare.

References

- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33.
- [2] Xiao Y, Torok ME. Taking the right measures to control COVID-19. Lancet Infect Dis 2020;20(5):523–4.
- [3] Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708–20.
- [4] World Health Organization. Laboratory diagnostics for novel coronavirus. https:// www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novelcoronavirus; 2020, Accessed date: 6 February 2020.
- [5] Fan Q, Pan Y, Wu Q, et al. Anal swab findings in an infant with COVID-19. Pediatr Invest 2020;4(1):48-50.
- [6] Liu J, Xiao Y, Shen Y, et al. Detection of SARS-CoV-2 by RT-PCR in anal from patients who have recovered from coronavirus disease 2019. J Med Virol 2020. https://doi. org/10.1002/jmv.25875. [Online ahead of print].
- [7] Wu J, Liu J, Li S, et al. Detection and analysis of nucleic acid in various biological samples of COVID-19 patients. Trav Med Infect Dis 2020:101673.
- [8] Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microb Infect 2020;9(1):386–9.

Rui Huang¹

Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China

Haiyan Zhao¹

Department of Infectious Diseases, Suqian People's Hospital of Nanjing Drum Tower Hospital Group, Suqian, China

Jian Wang, Xiaomin Yan

Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China

Huaping Shao

Department of Infectious Diseases, Suqian People's Hospital of Nanjing Drum Tower Hospital Group, Suqian, China

Chao Wu*

Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China E-mail address: dr.wu@nju.edu.cn.

¹ Rui Huang and Haiyan Zhao contributed equally.

^{*} Corresponding author. Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing, 210008, Jiangsu, China.